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Abstract
Renal functional deterioration is associated with physical and mental burdens for kidney
transplant (KT) and chronic kidney disease (CKD) patients. However, the change in health-
related quality of life (HRQOL) over time in KT patients compared to that of native CKD
patients has not been evaluated. We addressed this issue using KT patients registered in
the KNOW-KT cohort study and patients at CKD stage 1–3 registered in the KNOW-CKD
cohort study. HRQOL scores were assessed using the Kidney Disease Quality of Life Short
Form at baseline, 2-, and 4-years follow-up in 842 KT patients and at baseline and 5-year
follow-up in 1,355 CKD patients. SF-36 scores declined at the 4-year follow-up, whereas
CKD-targeted scores showed no change in the KT group. In contrast, CKD-targeted scores
as well as SF-36 scores were decreased at the 5-year follow-up in CKD patients. When
prognostic factors were analyzed for longitudinal HRQOL data over time, renal functions,
diabetes, cardiovascular and cerebrovascular diseases, hemoglobin level, marital status,
income, employment, and health care were significant prognostic factors. Furthermore, KT
was an independent prognostic factor for better HRQOL. These results highlight that KT can
offer a better HRQOL than that of CKD patients, even when renal function is similar.
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Introduction
Chronic kidney disease (CKD) patients suffer a worsening quality of life (QOL) along with an
increased risk of morbidity and mortality as their renal function deteriorates progressively [1,
2]. CKD patients, including dialysis patients, experience significant physical and mental bur-
dens such as fatigue, pruritus, sleep disturbance, pain, depression, and restless leg syndrome
[3–6], ultimately leading to an impaired physical and psycho-social health status [7]. This poor
QOL has been strongly associated with adverse clinical outcomes such as increased mortality,
morbidity, and frequent hospitalization in CKD patients [1, 8, 9]. In this sense, assessment of
health-related QOL (HRQOL) is useful to estimate the health status, disease burden, treatment
effectiveness, and even survival in CKD patients [10, 11]. Previous studies have shown that in
CKD patients, HRQOL is positively associated with the estimated glomerular filtration rate
(eGFR) level [12, 13], and deteriorates in line with progression through CKD stages [14].
Moreover, native CKD patients show higher QOL scores than hemodialysis patients but still
have lower QOL scores than the general population [15].
The two main goals of kidney transplantation (KT) are improvements in survival and QOL,
and the latter has received increased research attention in recent years. Several studies have
shown that patients who underwent successful KT had better HRQOL as well as improved sur-
vival compared to patients who received hemodialysis and peritoneal dialysis [16–18]. Further-
more, a lower HRQOL in KT patients was independently associated with post-transplant
mortality and morbidity. These findings suggest the importance of regular HRQOL assess-
ments in KT patients [19].
KT patients are considered to be a subgroup of the CKD population, since they have only a
single functional kidney and the recovered renal function also slowly declines over time [20].
The post-KT eGFR is frequently below 60 mL�min-1�1.73 m-2 and one report suggested that
32.3% of KT patients belonged to CKD stage 3b (eGFR <45 mL�min-1�1.73 m-2) 1 year after
transplantation [21]. Despite studies on changes in HRQOL over time in CKD patients, no
longitudinal study of QOL changes beyond 1 year after KT has been performed for this impor-
tant CKD subgroup. Moreover, the HRQOL patterns in KT patients and native CKD patients
with similar renal function have not been compared.
Therefore, the aim of this study was to investigate the longitudinal changes in HRQOL with
respect to both general health status and CKD-specific health status in KT patients, and to
compare these HRQOL patterns in KT and CKD patients at the same CKD stages. For this
analysis, we used data of patients enrolled in the KoreaN cohort study for Outcome in patients
With Kidney Transplantation (KNOW-KT) and the KoreaN cohort study for Outcome in
patients With Chronic Kidney Disease (KNOW-CKD) [22, 23].
Materials and methods
Ethics statement
This study protocol was approved by the Institutional Review Board at Seoul National Univer-
sity College of Medicine/Seoul National University Hospital (H-1901-124-1005) and was con-
ducted in accordance with the 1964 Declaration of Helsinki and its later amendments or
comparable ethical standards. All participants provided informed written consent.
Study design and participants
KNOW-KT and KNOW-CKD are ongoing multicenter, observational, cohort studies of
Korean KT and native CKD patients. The detailed study design of each cohort has previously
been published [22, 23]. In brief, the KNOW-KT study enrolled and followed up adult living-
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or deceased-donor KT patients annually, while the KNOW-CKD study enrolled and followed
up adult native CKD patients according to Kidney Disease Improving Global Outcomes Clini-
cal Practice Guideline annually [20]. Because of the relatively small number of KT patients at
CKD stage 4–5, data of patients at CKD stages 4 and CKD 5 were excluded. A total of 1,080
KT patients from eight Korean transplantation centers and 2,238 CKD patients from nine clin-
ical centers were registered in these studies from 2011 to 2016. Those who had never partici-
pated in the HRQOL questionnaire test were excluded from the analysis. The eGFR was
calculated by four-variable Modification of Diet in Renal Disease equations [24]. Primary out-
come is QOL at baseline and follow-up time points. Main exposures are kidney transplantation
vs. CKD, renal functions (eGFR), and follow-up time.
Data collection
Clinical information, including socio-demographic, medical histories, anthropometric, and
laboratory data, at baseline and at follow-up was reviewed. Demographic variables included
age, gender, marital status, monthly income, employment, and level of education. Higher edu-
cation was defined as graduation from college or graduate school. Higher income was defined
as a monthly family income higher than US $4,500. Employment was determined by the indi-
vidual work status at the time of questionnaire request. Higher education level was defined as a
final educational level of college diploma or above. Medical demographic data included pri-
mary cause of CKD, diabetes, hypertension, cardiovascular disease (CVD), and cerebrovascu-
lar disease. CVD was defined as heart failure or coronary arterial disease requiring
hospitalization and coronary intervention. Anthropometric measurements were performed
for height, weight, and body mass index (BMI), calculated as weight/height2 (kg/m2). The lab-
oratory parameters were hemoglobin, serum albumin, and serum creatinine. As KT group-
specific factors, the type of native dialysis modality, dialysis duration, donor type, and immu-
nosuppressive regimens were included in the analysis.
Assessment of HRQOL
QOL was assessed by self-administered questionnaires using the Kidney Disease Quality of Life
Short Form (KDQOL-SF, version 1.3) [25]. This questionnaire consists of a kidney-specific part,
CKD-targeted scores, and a general part, termed SF-36 [26, 27]. The KDQOL-SF has been vali-
dated for estimation of QOL in the Korean population and the KT population [26–28] as a multi-
dimensional tool, which makes it possible to conduct subdomain comparisons. In brief, the
CKD-targeted scores contain 43 kidney-specific items that are categorized into 11 subdomains:
symptoms/problems, effects of kidney disease, burden of kidney disease, work status, cognitive
function, quality of social interaction, sexual function, sleep, social support, encouragement by
the dialysis staff, and patient satisfaction with care. The SF-36 scores consist of 36 items that
belong to eight subdomains divided into the physical component summary (PCS) scores and
mental component summary (MCS) scores. The survey generates scores on 8 scales, 4 scales in
PCS and MCS, respectively. PCS includes physical functioning, role limitations due to physical
health, bodily pain, general health, and MCS includes vitality (energy), social functioning, role
limitations due to emotional problems, and mental health (emotional wellbeing). Responses to
each item were transformed into KDQOL-SF equivalent scores ranging from 0 to 100-point lin-
ear scores, with higher scores indicating better QOL. Self-administration is the principle of this
assessment; however, the questionnaire was completed with the help of a study assistant when a
patient had difficulty doing so. Assessment of HRQOL using KDQOL-SF was performed at 2
years after KT as the baseline and at the 2-year and 4-year follow-up in the KT group. HRQOL
assessment was performed at baseline and at the 5-year follow-up in the CKD group.
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Statistical analysis
Continuous variables were expressed as the mean ± standard deviation or median (interquar-
tile range), and categorical variables were expressed as number (percentage). The Student t-
test, Mann Whitney U test, or chi-square test was used for comparison, as appropriate. We
analyzed prognostic factors associated with higher HRQOL scores that were repeatedly-mea-
sured over multiple time-points. For this longitudinal statistical analysis over time, we used a
generalized estimated equation (GEE).
Follow-up time from baseline was included as time variable in this model. Multivariate
model included all covariates yielding unadjusted P value less than 0.2 as well as clinical
important variables such as age, gender, and eGFR without a selection algorithm. Two-sided P
values less than 0.05 were considered statistically significant. All statistical analyses were per-
formed using SPSS for Windows version 25.0 (IBM Corp., Armonk, NY, USA).
Results
Changes in HRQOL after KT
A total of 842 KT patients in the KNOW-KT cohort who had available baseline HRQOL data
at 2 years after KT or follow-up HRQOL data, were included in the final analysis (Fig 1A).
When baseline characteristics were compared between included subjects and excluded sub-
jects among KT patients with CKD stage 1–3 at baseline, there were no significant differences
in the clinical characteristics except for age between the two groups (S1 Table). The clinical
and laboratory characteristics of the final analysis set are summarized in Table 1. At the 2-year
follow-up, eGFR did not differ from baseline, whereas at the 4-year follow-up eGFRs were sig-
nificantly lower than baseline eGFRs. Both hemoglobin levels and albumin levels were signifi-
cantly lower at the 4-year follow-up compared to baseline.
The mean HRQOL scores were calculated at baseline, at the 2-year follow-up, and at the
4-year follow-up. The SF-36 scores, including both physical and mental QOLs and CKD-tar-
geted scores did not show significant changes at the 2-year follow-up (Fig 2). However, SF-36
scores had decreased significantly at the 4-year follow-up (Fig 2A). Both physical and mental
QOLs had decreased significantly at the 4-year follow-up (-2.5 points and -2.3 points, respec-
tively) (Fig 2B and 2C). In contrast, the CKD-targeted score did not change during follow-up
(Fig 2D). In the subdomain analysis of PCS, general health showed lower values at the 2-year
follow-up than at baseline. Among MCS categories, emotional well-being, social function, and
energy/fatigue showed significantly decreased values at the 4-year follow-up (Fig 2E). With
respect to the subdomain analysis for CKD-target scores, compositional scores showed incon-
sistent changes. The scores for work status, quality of social interaction, and sleep were slightly
decreased at the 4-year follow-up (Fig 2F).
When we classified patients to group of decline, no change, or improvement according to
QOL changes, decline, no change, and improvement of SF-36 score were found in 110
(56.1%), 3 (1.5%), and 83 (42.3%) patients, respectively. For CKD-targeted score, decline, no
change, improvement was found in 110 (56.1%), 3 (1.5%), and 83 (42.3%) patients,
respectively.
Prognostic factors associated with better HRQOL in KT recipients
We analyzed independent prognostic factors associated with higher HRQOL scores at the
4-year follow-up. Analysis using a GEE revealed that absence of diabetes mellitus, higher
blood hemoglobin level, higher income, married status, and current employment were associ-
ated with higher SF-36 scores (Table 2). Younger age, absence of hypertension, absence of
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Fig 1. Flow diagram of the study population. (A) Among 1,080 KNOW-KT cohort participants, total 842 patients were
analyzed after exclusion of 238 people. (B) Among 2,238 KNOW-CKD cohort participants, total 1,355 patients were
analyzed after exclusion of 883 people. KNOW-KT, KoreaN cohort study for Outcome in patients With Kidney
Transplantation; QOL, quality of life; KNOW-CKD, KoreaN cohort study for Outcome in patients With Chronic Kidney
Disease.
https://doi.org/10.1371/journal.pone.0257981.g001
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diabetes mellitus, higher eGFR, higher income, married status, and current employment were
associated with higher CKD-targeted scores (Table 2).
Changes in HRQOL over time in CKD patients
A total of 1,355 CKD patients in the KNOW-CKD cohort with available HRQOL data at base-
line or follow-up HRQOL data were included in this study (Fig 1B). When baseline character-
istics were compared between included subjects and excluded subjects among patients with
CKD stage 1–3 at baseline, the excluded patients were older than the included patients. Diabe-
tes and hypertension were more frequent in the excluded group (S2 Table). The clinical and
laboratory characteristics of the final analysis set are described in Table 1.
In the CKD population, renal function decreased significantly over time (64.3 ± 26.6
mL�min-1�1.73 m-2 at baseline vs. 57.3 ± 28.4 mL�min-1�1.73 m-2 at 5 years; P = 0.001). In
addition, both the SF-36 and CKD-targeted scores were decreased at the 5-year follow-up
(S1A and S1D Fig). The mean changes in QOL scores between baseline and the 5-year follow-
up were higher for CKD-targeted scores than for SF-36 (-1.5 and -0.85 points, respectively).
Physical QOL was also significantly decreased at 5 years compared to the baseline levels (S1B
Table 1. Comparison of clinical characteristics between KT and CKD patients at baseline.
Variables CKD (N = 1355) KT (N = 842) P�
Age (years, mean ± SD) 52.5 ± 12.5 45.3 ± 11.7 0.001
Male gender (%) 829 (61.2%) 531 (63.1%) 0.391
Marriage (%) 1106 (81.6%) 615 (73.0%) 0.034
Education (%)
College or post-graduate 638 (47.1%) 429 (51.0%) 0.250
Economy (%)
High (> $ 4,500/ month) 333 (24.6%) 131 (15.6%) 0.134
Current employment (%) 826 (61.6%) 426 (50.6%) 0.021
Health insurance (%) 1238 (91.4%) 781 (92.8%) 0.184
BMI (kg/m2, mean ± SD) 24.6 ± 3.4 22.6 ± 3.2 0.001
Cause of ESRD (%) 0.014
DM 218 (16.1%) 161 (19.1%)
HTN 223 (16.5%) 246 (29.2%)
GN 545 (40.2%) 269 (31.9%)
ADPKD 290 (21.4%) 44 (5.2%)
Others 79 (5.8%) 122 (14.5%)
DM 334 (24.6%) 201 (23.8%) 0.487
Hypertension 999 (73.7) 775 (92.0%) 0.020
Cardiovascular disease 85 (6.3%) 48 (5.7%) 0.395
Cerebrovascular disease 69 (5.1%) 29 (3.4%) 0.972
eGFR (mL/min/1.73 m2, mean ± SD)
Baseline 63.3 ± 27.2 66.0 ± 17.0 0.009
Hemoglobin (g/dL, mean ± SD)
Baseline 13.5 ± 1.9 13.9 ± 1.9 0.001
Albumin (g/dL, mean ± SD)
Baseline 4.2 ± 0.4 4.4 ± 0.3 0.001
ADPKD, autosomal dominant polycystic kidney disease; BMI, body mass index; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate by MDRD equation;
ESRD, end-stage renal disease; GN, glomerulonephritis; HD, hemodialysis; HTN, hypertension; SD, standard deviation.
�P < 0.05, CKD patients vs. KT patients (Paired t-test).
https://doi.org/10.1371/journal.pone.0257981.t001
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Fig). However, mental QOL showed no significant difference between baseline and the 5-year
follow-up (S1C Fig). Among the SF-36 subdomains, scores for role limitations due to physical
problems (-3.2 points) were most remarkably decreased (S1E Fig). With respect to the CKD-
target score, sexual dysfunction (-8.2 points), impaired work status (-4.6 points), kidney-dis-
ease effects (-4.3 points), and sleep (-2.8 points) were markedly decreased at the 5-year follow-
up (S1F Fig).
Decline, no change, and improvement of SF-36 score during follow up were found in 392
(53.9%), 10 (1.4%), and 325 (44.7%) patients, respectively. Decline, no change, and improvement
of the CKD-targeted score were found in 423 (58.2%), 0%, and 304 (41.8%) patients, respectively.
Prognostic factors associated with better HRQOL in CKD patients
Analysis using a GEE revealed that absence of diabetes, absence of cerebrovascular disease,
higher hemoglobin level, male gender, married status, higher education, higher income, cur-
rent employment, and health insurance were independently associated with higher SF-36
scores at the 5-year follow-up in the CKD patients (S3 Table). Absence of diabetes, absence of
Fig 2. Changes in SF-36 scores and CKD-targeted scores after kidney transplantation. (A) HRQOL at baseline, 2- and 4-year follow-up was assessed by
SF-36 scores in kidney transplant patients. (B-C) Physical component summary (PCS) score (B) and mental component summary (MCS) score (C) were
also assessed. (D) Total CKD-targeted score was assessed by KDQOL-SF at baseline, 2- and 4-year follow-up. All values in panel a-d were displayed using
Box and whisker plots. Top, middle, and bottom of boxes were the 75th, 50th, and 25th percentiles, respectively; whiskers illustrate the range. (E, F) Each
domain covering PCS or MCS scores in SF-36 scores (E) and the CKD-targeted scores (F) was separately analyzed. Each value in panel e and f was
displayed as the mean ± standard error of the mean. �P<0.05 and ��P<0.01 compared to baseline (paired t-test). CKD, chronic kidney disease; HRQOL,
health-related quality of life; KDQOL-SF, Kidney Disease Quality of Life Short Form; SF-36, Short Form-36 Health Survey (SF-36).
https://doi.org/10.1371/journal.pone.0257981.g002
Table 2. Prognostic factors associated with HRQOL in KT patients a.
Parameter Higher SF-36 score Higher CKD-targeted score
Estimate (95% C.I.) SE P Estimate (95% C.I.) SE P
Time -0.603 (-3.281, 1.276) 1.109 0.169 -0.193 (-2.243, 1.813) 1.042 0.848
Age -0.081 (-0.189, 0.078) 0.057 0.154 -0.124 (-2.124, 3.439) 0.048 0.009
Gender (Male) 0.270 (-1.412, 1.402) 1.182 0.819 2.381 (0.318, 4.444) 1.053 0.024
Hypertension -2.358 (-7.432, 2.273) 2.399 0.326 -3.575 (-6.931, -0.222) 1.712 0.037
Diabetes mellitus -5.207 (-7.889, -2.396) 1.275 < 0.001 -2.659 (-4.651, -0.534) 1.063 0.012
Cardiovascular Ds -3.229 (-7.538, 1.654) 2.124 0.128 -1.177 (-4.538, 2.183) 1.770 0.492
Cerebrovascular Ds -0.579 (-6.388, 5.231) 2.872 0.845 -1.152 (-5.546, 2.393) 2.394 0.630
BMI -0.068 (-0.349, 0.226) 0.155 0.659 -0.092 (-0.407, 0.189) 0.129 0.476
eGFR 0.030 (-0.037, 0.076) 0.025 0.372 0.053 (0.008, 0.097) 0.021 0.020
Albumin 1.500 (-2.316, 5.317) 1.215 0.247 0.657 (-2.124, 3.439) 1.012 0.648
Hemoglobin 0.627 (0.108, 1.291) 0.346 0.020 0.241 (-0.249, 0.731) 0.289 0.335
Marriage 3.471 (0.208, 5.315) 1.364 0.011 4.304 (1.832, 6.038) 1.137 <0.001
Higher education b 0.982 (-1.368, 3.002) 1.109 0.376 -1.222 (-2.958, 0.594) 0.924 0.186
Higher income c 3.367 (1.493, 6.015) 1.267 0.010 2.527 (1.210, 4.285) 1.056 0.017
Employment 2.629 (0.356, 4.687) 1.105 0.017 5.911 (3.989, 7.616) 0.921 <0.001
Health insurance (vs. Health care) 1.678 (-3.202, 5.912) 2.017 0.560 1.051 (-2.477, 4.580) 1.681 0.559
BMI, body mass index; C.I., confidence interval; CKD, chronic kidney disease; Ds, Disease; eGFR, estimated glomerular filtration rate by MDRD equation; KT, kidney
transplantation; SE, standard error.
a Generalized estimated equation analysis was performed.
b Higher education was defined as receiving a diploma from college or higher.
c Higher income was defined as monthly income above $ 4,500. P value by generalized estimated equation analysis.
https://doi.org/10.1371/journal.pone.0257981.t002
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cerebrovascular disease, higher eGFR at baseline, higher blood hemoglobin level, male gender,
married status, higher income, current employment, and health insurance were independently
associated with higher CKD-targeted scores at the 5-year follow-up (S3 Table).
Comparison of HRQOL changes in KT and CKD populations
Next, we compared the HRQOL changes over time in KT and native CKD patients. The base-
line, 2-, and 4-year follow-up data of KT patients were compared with the baseline and 5-year
data of CKD patients (Fig 3A–3D). When clinical characteristics were compared between the
KT and CKD group (Table 1), the CKD patients were significantly older than the KT patients
(52.5 ± 12.5 vs. 45.3 ± 11.7 years, P = 0.001). The SF-36 scores were higher in KT patients than
in CKD patients at baseline (78.2 ± 12.8 vs. 73.9 ± 15.6, P = 0.001), whereas the CKD-targeted
scores were similar between the two groups at baseline (74.3 ± 12.0 vs. 74.9 ± 12.3, P = 0.261).
During follow-up, SF-36 scores as well as PCS scores and MCS scores were higher in the KT
population than in the CKD population during the study period (Fig 3A–3C). However, the
CKD-targeted score over time remained similar between the two groups, although the differ-
ence seemed to increase over time (Fig 3D).
A GEE analysis of the combined population of KT and CKD patients also demonstrated
that KT was significantly associated with a higher SF-36 score (P< 0.0001) along with absence
of diabetes, absence of CVD, absence of cerebrovascular disease, higher hemoglobin level,
married status, higher education, higher family income, current employment, and health
insurance (Table 3 and Fig 3A). Renal function (eGFR) showed a borderline significance for
SF-36 (P = 0.058, Table 3). However, KT was not associated with higher CKD-targeted scores
(P = 0.561). Instead, renal function (P = 0.003) was a significant prognostic factor for CKD-tar-
geted scores along with male gender, absence of diabetes, absence of CVD, absence of cerebro-
vascular disease, higher hemoglobin level, married status, higher family income, current
employment, and health insurance (Table 3).
Comparison of HRQOL changes in KT and CKD populations according to
CKD stages
In patients with CKD stage 1–2, higher baseline SF-36 scores in the KT patients decreased
slightly, there were no changes in the scores of CKD patients, and the scores of the two groups
were more similar at the later part of follow-up (Fig 3E and S4 Table). In contrast, the differ-
ence in SF-36 scores between stage 3 KT patients and CKD patients increased during follow-
up (GEE, interaction of group and time, P = 0.031, Fig 3F and S5 Table).
CKD-targeted scores also showed different change patterns over time according to baseline
CKD stages. There was no significant difference in CKD-targeted scores over time between
KT and CKD patients irrespective of CKD stage (Fig 3G and 3H). However, in CKD stage 3,
the difference in the CKD-targeted scores seemed to increase over time (GEE, interaction of
group and time, P = 0.009, Fig 3H and S5 Table).
Discussion
The present cohort study demonstrated that KT patients had higher SF-36 scores with respect
to both physical and mental QOL than CKD patients at the same CKD stage; however, they
had similar CKD-targeted scores compared to CKD patients with similar renal function. KT
was a significant prognostic factor associated with better QOL, independent of renal function.
CKD patients suffer from a low QOL [1, 2]. The AUSDiab analysis reported that physical
QOL in CKD patients decreased in parallel with eGFR decline during a 5-year follow-up [29].
Consistently, our study showed that SF-36 scores, mainly PCS scores decreased over 5 years.
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Fig 3. Comparison of changes in HRQOL between KT and CKD patients at the similar renal function according to CKD stage.
(A) SF-36 score at CKD stage 1–3. (B) PCS score at CKD stage 1–3. (C) MCS score at CKD stage 1–3. (D) CKD-targeted score at CKD
stage 1–3. (E) SF-36 score at CKD stage 1–2. (F) SF-36 score at CKD stage 3. (G) CKD-targeted score at CKD stage 1–2. (H) CKD-
targeted score at CKD stage 3 were compared between KT (solid lines) and CKD patients (dot lines). Each value was displayed as the
mean ± standard error of the mean. Chronic kidney disease; MCS, mental component summary score; KT, kidney transplantation;
PCS, Physical component summary score.
https://doi.org/10.1371/journal.pone.0257981.g003
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The CKD-targeted score also decreased along with decreasing renal function, and better renal
function was independently associated with higher CKD-targeted QOL, in line with previous
studies [7, 12, 29]. A Korean community-based analysis also showed that QOL was inversely
correlated with CKD stage [30]. Taken together, these findings clearly demonstrate that QOL
in CKD patients becomes worse along with decreasing renal function, which is an important
prognostic factor associated with QOL in CKD patients.
KT immediately improves the renal function of ESRD patients. A Greek study demonstrated
improvement in QOL components such as better general health perception, role of emotional
function, and vitality among the subdomains of the SF-36 score in KT patients 1 year after
transplantation [31]. A recent US study reported deterioration of physical QOL and a stationary
CKD-targeted score at 1 month after KT, but significant improvements in physical and CKD-
targeted QOL at 3 months, especially for more frail patients [32]. We also previously reported
significant improvements in HRQOL for both SF-36 and CKD-targeted QOL scores at 2 years
after KT [33]. Furthermore, the present follow-up study of a larger group demonstrated that the
improved QOL at 2 years after KT began to decline at 4-year follow-up in the KT group.
Previous studies have assessed the association between QOL at the early phase with long-
term clinical outcomes such as mortality and allograft function in KT populations. Higher
physical and mental health scores are significant prognostic factors for better 10-year survival
[34], and lower physical function and general health perception in the physical component are
independent risk factors for 7-year mortality [19]. We hope that further long-term follow-up
studies using our KT cohort can demonstrate the impact of QOL at each time-point and its
influence on the long-term clinical outcomes after KT.
Table 3. Prognostic factors associated with HRQOL in the total population including both KT and CKD patients a.
Parameter Higher SF-36 score Higher CKD-targeted score
Estimate (95% C.I) SE P Estimate (95% C.I.) SE P
KT (vs. CKD) 8.760 (5.290, 9.414) 1.041 < .0001 0.428 (-1.102, 1.941) 0.735 0.561
Time -1.457 (-3.585, 1.408) 1.450 0.315 -0.462 (-2.902, 2.289) 1.333 0.729
eGFR 0.028 (-0.055, 0.058) 0.015 0.058 0.037 (0.011, 0.058) 0.012 0.003
Age -0.011 (-0.085, 0.028) 0.034 0.753 -0.031 (-0.064, 0.026) 0.027 0.236
Gender (Male) 0.032 (-1.358, 1.422) 0.789 0.083 1.024 (0.085, 2.134) 0.566 0.040
Hypertension -1.367 (-3.035, 0.714) 1.054 0.195 -0.156 (-1.495, 1.082) 0.818 0.849
Diabetes mellitus -4.662 (-5.829, -2.501) 0.881 < .0001 -3.035 (-4.127, -1.353) 0.683 < .0001
Cardiovascular Ds -3.683 (-6.471, -0.257) 1.561 0.018 -2.634 (-4.537, -0.195) 1.211 0.030
Cerebrovascular Ds -4.121 (-7.405, -1.120) 1.787 0.021 -3.511 (-6.578, -0.903) 1.387 0.011
BMI -0.079 (-0.292, 0.134) 0.109 0.524 -0.047 (-0.222, 0.127) 0.089 0.594
Albumin 1.357 (-0.754, 3.467) 1.076 0.208 1.381 (-0.147, 3.015) 0.705 0.075
Hemoglobin 1.153 (0.544, 2.337) 0.230 < .0001 0.704 (0.423, 1.047) 0.178 < .0001
Marriage 3.585 (1.766, 5.341) 1.021 0.0004 4.818 (3.411, 6.190) 0.792 < .0001
Higher education b 2.965 (1.000, 3.750) 0.771 0.010 0.085 (-0.981, 1.150) 0.598 0.876
Higher income c 3.249 (1.980, 4.725) 0.904 0.0003 2.164 (1.414, 3.735) 0.701 0.002
Employment 3.899 (2.243, 5.203) 0.789 < .0001 6.731 (5.384, 7.613) 0.612 < .0001
Health insurance (vs. Health care) 4.962 (1.313, 9.083) 1.657 0.003 3.602 (0.569, 5.899) 1.285 0.017
BMI, body mass index; C.I., confidence interval; CKD, chronic kidney disease; Ds, Disease; eGFR, estimated glomerular filtration rate by MDRD equation; KT, kidney
transplantation; SE, standard error.
a Generalized estimated equation analysis was performed.
bHigher education was defined as receiving a diploma from college or higher.
c Higher income was defined as monthly income above $ 4,500. P value by generalized estimated equation analysis.
https://doi.org/10.1371/journal.pone.0257981.t003
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We investigated the prognostic factors associated with QOL in KT and CKD cohorts. A sin-
gle-center study in Thailand reported that gender, marital status, higher income, and higher
education were associated with increased QOL after KT [35]. In the present study, absence of
diabetes mellitus, higher blood hemoglobin level, higher monthly income, marriage, and
employment were independently associated with higher SF-36 scores in KT or CKD patients.
The CKD-targeted score was significantly associated with decreased renal function, absence of
diabetes, higher income, employment, and married status in both the KT and CKD groups.
The hemoglobin level consistently influenced QOL in KT and CKD patients [36–38]. Diabetes
was another important prognostic factor influencing QOL in the present KT population in
parallel with reports of non-KT populations [39]. These findings suggest that efforts are
needed to improve QOL during the pre-KT CKD phase to achieve a better post-KT QOL
along with correction of anemia.
Because KT patients remain in a state of CKD, we tried to explore differences in QOL
between KT and non-KT CKD patients with similar renal function. Previous studies demon-
strated that KT patients had better QOL than ESRD patients undergoing dialysis [17, 40–43].
The overall improvement in QOL after KT was mostly attributed to improvement of physical
function [44]. However, few studies have compared QOL between KT patients and native
CKD patients. A small-sized, single-center study that compared 38 stable KT recipients and 38
CKD patients at CKD stage 3b–4 showed no significant difference in the SF-36 QOL score, but
a better QOL in non-dialysis CKD patients than in KT patients based on a visual analogue
scale [45]. In contrast, in the present multicenter study, KT patients had higher SF-36 QOL
scores than the CKD patients after adjustment for other factors, including renal function.
These positive effects of KT on QOL were observed in various domains of the MCS and in the
general health domain of the PCS. When we analyzed the impact of KT on QOL over time
compared to CKD according to CKD stages, SF-36 scores were higher in KT patients than in
CKD patients at CKD stage 3 as well as CKD stages 1–2. On the other hand, CKD-targeted
scores in KT and CKD patients did not differ at baseline and there was no significant differ-
ence in the change of CKD-targeted scores over time between the two groups irrespective of
CKD stage. Interestingly, the difference in both SF-36 and CKD-targeted scores between the
two groups increased over time at CKD stage 3, suggesting that the beneficial effects of KT on
HRQOL compared to CKD might increase with CKD progression. Overall, KT patients had
better SF-36 scores than CKD patients independent of renal function, whereas the CKD-tar-
geted score was mainly dependent on renal function and KT did not provide additional bene-
fits in patients with similar renal function.
Some of baseline characteristics except renal functions, such as age, BMI, albumin levels,
hemoglobin levels, marriage status, and current employment, were different between the KT
group and the CKD group. However, the KT group showed better QOL than the CKD group
after adjustment of these different factors by multivariate analysis.
The reasons why KT patients have better QOL than CKD patients with similar renal func-
tion are unclear. KT patients might interpret their QOL more positively than CKD patients,
which may be related to their history of improvement with KT and lower levels of concern
about future prognosis compared to CKD patients without a dramatic recovery experience.
Indeed, depression was found to be the most important factor influencing HRQOL in the
CKD population [46]. Depressive mood consists of lack of enthusiasm, feelings of hopelessness
for the future, feeling left behind in society, and an associated feeling of worthlessness, which
may result in a poor QOL at advanced CKD stages. In contrast, the KT population considered
the possibility of recovering renal function with treatment or retransplantation, which might
bring hope and reduce depressive mood. The higher QOL in KT patients might allay fears
related to disease progression so as to conform to the CKD status.
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This study had several limitations. First, the number of patients at the 4-year follow-up was
relatively small in the KT population. Second, this study did not include advanced CKD stage
4–5 patients because of low numbers, so we could not compare KT and CKD patients at this
advanced stage. Therefore, further longer-term follow-up studies using this cohort could help
to more adequately assess the association between renal functional deterioration and QOL
changes in KT patients, and the impact of KT on QOL compared to CKD in advanced CKD
stages. Third, unfortunately the follow-up time-points of serial QOL assessment were different
in the KT and CKD cohorts. Furthermore, KT patients have had longer exposure time to
chronic kidney disease than native CKD patients and cannot exclude a possibility that different
exposure time might have influenced different QOL between CKD with transplanted kidneys
and CKD with native kidneys at similar renal functions. Future comparative studies with the
same follow-up schedule are needed to confirm our findings. Fourth, we did not include
healthy subjects with normal kidney function in this study. Further study to compare QOL
between the healthy control and the KT group could estimate benefits in QOL in the KT group
more clearly. Finally, we used MDRD equation to estimate eGFR in both native CKD and KT
population. However, MDRD equation is not a gold standard to calculate eGFR in KT patients.
Some data showed CKD-EPI equation has least bias to evaluate eGFR in KT population com-
pared to MDRD [47]. However, because CKD-EPI method overestimates eGFR in CKD stage
1 and 2, MDRD method was recommended as a good tool to assess eGFR in KT population
[48]. Furthermore, MDRD equation was accurate and least bias in other studies [49]. Because
no calculation method for eGFR in transplant patients perfectly represents measured GFR in
whole range of GFR, application of the same tools in two groups could be reasonable.
Despite these limitations, to the best of our knowledge, this prospective, longitudinal
HRQOL study represents the longest follow-up QOL assessment of KT patients at multiple
time-points. Furthermore, this is the first study to compare QOL between KT and CKD
patients with similar renal function and a mild to moderate degree of CKD (stage 1–3). Based
on this study, further studies using other cohorts could confirm our findings.
In conclusion, KT patients have better QOL than CKD patients with similar renal function at
CKD stages 1–3. Therefore, improvement in QOL is an important benefit of KT for CKD patients.
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